Study of STAR-001 and spironolactone for returning glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called STAR-001 combined with spironolactone for people whose glioblastoma (a type of brain tumor) has come back. The goal is to see if the combination is safe and can shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of brain tumor called glioblastoma that has returned after first treatment.
- You are between 18 and 69 years old.
- You have not had more than one previous treatment for your brain tumor.
- You are healthy enough to perform daily activities (Karnofsky score of 70% or higher).
- You can provide a sample of your tumor tissue from a previous surgery or biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a new treatment called STARLITE for people with fast-growing brain tumors (high-grade gliomas) that cannot be safely removed with surgery. The treatment uses a laser to destroy the tumor from the inside. It may be a good option if you haven't had any prior treatment for this tumor.
This trial is testing a new drug (JL15003) given directly into the brain tumor using a small device called an Ommaya reservoir. It is for people whose glioblastoma has come back despite standard treatments. You will need to have had a polio vaccine booster before starting.
This early study tests whether a device called TheraSphere is safe when delivered into the brain to treat recurrent glioblastoma. It may help patients by trying a targeted treatment approach, while doctors carefully monitor side effects and safety.
This early trial tries to find which medicines might work best for your specific glioblastoma, by testing drugs on cancer “stem cell” samples. If the test finds promising drug options, it may guide a more personalized treatment approach.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.